These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20831047)

  • 1. [Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study].
    Sychev DA; Antonov IM; Ignat'ev IV; Naumova IuV; Dmitriev VA; Kropacheva ES; Dobrovol'skiĭ OB; Panchenko EP; Tashenova IA; Kukes VG
    Kardiologiia; 2010; 50(5):42-6. PubMed ID: 20831047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology consultation on warfarin pharmacogenetic testing.
    Stack G;
    Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
    [No Abstract]   [Full Text] [Related]  

  • 5. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
    Schwartz JB; Kane L; Moore K; Wu AH
    J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
    Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
    Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
    Eckman MH; Rosand J; Greenberg SM; Gage BF
    Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].
    Sychev DA; Ignat'ev IV; Kropacheva ES; Emel'ianov NV; Milovanova VV; Naumova IuA; Kosovskaia AV; Dobrovol'skiĭ OB; Tashenova AI; Panchenko EP; Kukes VG
    Vestn Ross Akad Med Nauk; 2011; (3):7-10. PubMed ID: 21544933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic testing for warfarin dosing: we are ready now.
    Wu AH
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].
    Kokh NV; Slepukhina AA; Tsvetovskaya GA; Lifshits GA
    Kardiologiia; 2015; 55(4):57-60. PubMed ID: 26502504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
    Gage BF; Eby C; Johnson JA; Deych E; Rieder MJ; Ridker PM; Milligan PE; Grice G; Lenzini P; Rettie AE; Aquilante CL; Grosso L; Marsh S; Langaee T; Farnett LE; Voora D; Veenstra DL; Glynn RJ; Barrett A; McLeod HL
    Clin Pharmacol Ther; 2008 Sep; 84(3):326-31. PubMed ID: 18305455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
    N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
    Epstein RS; Moyer TP; Aubert RE; O Kane DJ; Xia F; Verbrugge RR; Gage BF; Teagarden JR
    J Am Coll Cardiol; 2010 Jun; 55(25):2804-12. PubMed ID: 20381283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.
    Sconce EA; Kamali F
    Eur J Haematol; 2006 Dec; 77(6):457-62. PubMed ID: 17042764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
    You JH; Tsui KK; Wong RS; Cheng G
    Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.